Arrowhead Pharmaceuticals Inc (ARWR)

Quick ratio

		Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Cash	US$ in thousands	99,200	69,400	127,700	58,200	102,991	105,300	135,000	202,200	100,705	139,439	86,408	91,587	184,434	326,000	372,400	139,921	143,583	219,323	256,700	461,032
Short-term investments	US$ in thousands	578,276	367,300	395,410	162,064	292,700	346,400	346,046	299,582	268,391	277,057	315,487	364,557	310,083	316,738	330,734	251,418	256,929	67,709	50,959	40,969
Receivables	US$ in thousands	—	—	—	—	—	1,247	69,434	39,568	1,410	239	1,317	150	10,255	671	955	9,002	846	21,693	1,266	1,345
Total current liabilities	US$ in thousands	103,168	96,714	65,175	63,723	105,456	70,227	87,151	122,009	138,850	128,212	138,857	137,032	146,536	195,434	167,188	25,094	40,682	42,783	53,333	73,695
Quick ratio		6.57	4.52	8.03	3.46	3.75	6.45	6.32	4.44	2.67	3.25	2.90	3.33	3.44	3.29	4.21	15.95	9.87	7.22	5.79	6.83

September 30, 2024 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($99,200K + $578,276K + $—K) ÷ $103,168K
= 6.57

The quick ratio of Arrowhead Pharmaceuticals Inc has shown some fluctuations over the past quarters. It has generally been above the ideal value of 1, indicating a strong ability to cover its short-term obligations with its most liquid assets.

In the most recent quarter, as of September 30, 2024, the quick ratio stands at 6.57, which is significantly higher compared to the previous quarter. This indicates an improvement in the company's short-term liquidity position.

Looking back further, the quick ratio has varied between 2.67 and 8.03 over the last few quarters, showing some volatility but generally remaining at healthy levels. The exceptionally high quick ratio of 15.95 as of December 31, 2020, may suggest an unusually high level of liquidity at that time.

Overall, the trend in Arrowhead Pharmaceuticals Inc's quick ratio suggests that the company has maintained a strong ability to meet its short-term obligations with its readily available assets, providing a buffer against financial strain.